However, in phase III trials, combination of the BRAF inhibitor, dabrafenib, and the MEK inhibitor, trametinib, resulted in improved progression-free survival, and overall response and survival rates compared to dabrafenib monotherapy in untreated patients who had metastatic melanoma with BRAF V600E or V600K mutations [209]. Here, MAP2K7 is linked to metastatic melanoma.